Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_1073_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
31.08.2026
Размер:
22 Мб
Скачать
Chronic andRefractory Anal Fissure:
https://t.me/medicina_free
What Are theTreatment Options?
Ga-ramHan andNitinMishra
Introduction
Anal ssures are one of the most common causes of perianal pain with a cumulative lifetime risk of 11% [1]. Most acute anal ssures resolve with conservative manage­ment using stool softeners and ber supplements to ensure bulky, soft and regular bowel movements. The regimen can also include sitz baths, and topical analgesics such as lidocaine gel [2]. In a small but signicant number of patients, symptoms persist for longer than 4 to 8weeks, at which time it is categorized as a chronic anal ssure (CAF). The underlying pathophysiology leading to a tear in the anoderm is not fully understood, but it is thought that they may result from local trauma caused by a hard bowel movement or explosive diarrhea further exacerbated by chronic ischemia from a hypertonic anal sphincter.
Multiple non-operative and operative treatments for CAF have been studied with varying degrees of healing, recurrence, and side effects. The goal of most of these treatments is to reduce sphincter tone or spasm which in turn improves the blood supply to the anal mucosa to allow for wound healing. Some operative methods such as mucosal advancement aps are focused on wound coverage, and therefore, may be more appropriate for patients without high anal sphincter tone. Medical therapies are typically employed initially but have a lower rate of healing and higher rate of recurrence when compared to surgical procedures. Internal sphincterotomy
40
G.-r. Han Department of General Surgery, Division of Colon and Rectal Surgery, Mayo Clinic, Phoenix, AZ, USA e-mail: Han.Ga-ram@mayo.edu
N. Mishra (*) Department of Colon and Rectal Surgery, Mayo Clinic, Phoenix, AZ, USA e-mail: Mishra.Nitin@mayo.edu
© The Author(s), under exclusive license to Springer Nature Switzerland AG 2023 K. Umanskiy, N. Hyman (eds.), Difcult Decisions in Colorectal Surgery, Difcult Decisions in Surgery: An Evidence-Based Approach,
https://doi.org/10.1007/978-3-031-42303-1_40
451
452
https://t.me/medicina_free
Table 40.1 PICO table
P (Patients) Patients with
chronic or recurrent anal ssure
I (Intervention) C (Comparator)
Surgical management
Non-operative management (Medical therapy, Botulinum toxin injection)
G.-r. Han and N. Mishra
O (Outcomes) Cure, Recurrence,
Postoperative incontinence, Side-effects
is the most effective treatment but may lead to transient or permanent anal inconti­nence. Given these nuances, choosing the most appropriate treatment for patients with chronic or recurrent anal ssures can be challenging.
Search Strategy
A comprehensive literature search of PubMed, MEDLINE, and the Cochrane Database of Systematic Reviews and Central Register of Controlled Trials was per­formed from 2012 to 2022 to identify all English-language publications in adult patients related to treatment outcomes for chronic or refractory anal ssure (Table40.1). A combination of keywords and subject headings included “ssure in ano” or “chronic and refractory anal ssure” or “chronic anal ssure” or “refractory anal ssure” or “anal ssure” and “surgical aps” or “sphincterotomy” or “ssurec­tomy” or “surgical procedures” or “surgery” or “drug therapy” or “topical nitrate” or “botulinum toxin injection” or “nifedipine” or “diltiazem” or “topical calcium channel blocker” or “calcium channel blockers” and “treatment outcome” or “out­come” or “recurrence” or “cure” or “incontinence” or “pain” or “bleeding” or “infection” or “pelvic sepsis” or “complications.” A total of 149 papers were identi­ed in the searches. After Endnote de-duplication, there were 128 remaining papers. Exclusion criteria consisted of results that were out of scope or did not address treatment options for chronic or refractory anal ssures. The results were further ltered to include only systematic reviews, meta-analyses, and randomized con­trolled trials (RCT). Publications that contained inconsistent results between the body of the text and the tables or gures were also excluded. Ultimately, our search strategy produced 29 studies for inclusion– 18 RCTs (Table40.2) and 11 system­atic reviews or meta-analyses (Table40.3).
Results
Treatment options that have been investigated for management of CAF include medical therapy with topical nitrates or topical calcium channel blockers (CCB), botulinum toxin injection (BT), operative interventions such as lateral internal sphincterotomy (LIS), anal advancement aps (AAF), ssurectomy, or anal dila­tion, and a combination of these various treatments. With each of these treatment options, patients are encouraged to continue the conservative therapies for anal
40 Chronic andRefractory Anal Fissure: What Are theTreatment Options?
https://t.me/medicina_free
DTZ is
Pruritis;
5.3% ED
recommended
Pruritis
DTZ is more
Conclusions
100% HA;
NR
Incontinence
rate A/E
effective with
fewer A/E
48%
Constipation;
40% Pruritis
5.6%
Constipation;
8.3% Pruritis
These agents are
not signicantly
superior to each
other
11.1%
Pruritis
11.1%
Pruritis;
5.6%
Perianal
dermatitis
26.3%
over captopril due
to pruritis with
captopril. They
are equally
effective in
7% Mild HA.
3.8% Vertigo.
3.8%
Constipation.
453
managing
symptoms of
CAF.
(continued)
Recurrence
rate
Resolution of
pain
Rate of
healing
Yr F/U Pt, n Intervention: n
2% DTZ: 36 91.7% 100% NR NR No HA;
77.8% 55.6% NR 0% 22.2% HA;
5 mononitrate: 18
2% DTZ: 18 72.2% 27.8% NR 0% 5.6% HA;
55 0.2% Isosorbide
for
complications
Review after 8
wk
NR NR 45.8%
73.7% 42.1% NR 0% 15.8% HA;
2% DTZ + 0.1%
NR NR.No
Isosorbide 5
mononitrate: 19
50 0.5%
signicant
difference in
reduction of
pain scores.
Captopril: 24
2% DTZ: 26 NR NR NR No pruritis.
days for 60
days
Comparing topical medications
Ala 2012 Review q2 wk 61 0.2% GTN: 25 60% 100% NR
First Author
Table 40.2 Randomized controlled trials studying the treatment of chronic and refractory anal ssures
Bulus 2013 Review at 1 wk
Ala 2015 Review q10
454
https://t.me/medicina_free
Nifedipine has a
higher healing
rate and fewer
Conclusions
A/E.
outcomes in
recurrences and
healing and
reduction of
symptoms
greater and
quicker healing
with fewer
adverse effects,
but post- treatment
pain scores were
lower with GTN.
G.-r. Han and N. Mishra
acetate had lower
pain scores,
higher healing
rate and a lower
recurrence rate.
ushing)
Incontinence
rate A/E
Recurrence
rate
Resolution of
pain
Rate of
healing
82.5% NR 18.1% NR 6.9%
0.5%
Nifedipine: 45
2% DTZ: 92 80.4% 72.8% NR NR NR
NR None 6.6% Pruritis Minoxidil had
NR.Both
had a
signicant
decrease in
(shorter
duration to
healing)
(21.9% HA,
15.6%
pain scores
with a
signicantly
lower score
0.2% GTN: 32 46.9% NR None 40.6%
Postural
hypotension,
3.1%
with GTN.
Palpitations)
86.3% 87.5% 2.9% NR None Tocopherol
acetate: 80
Mild-
0.4% GTN: 80 66.3% 70% 13.2% NR 27.5%
moderate
HA, 17.5%
Severe HA
90 2% GTN: 45 60% NR 23.8% NR 16.6% (HA,
for 2 mo for
healing.
Review q2 mo
for 6 mo for
recurrence
Yr F/U Pt, n Intervention: n
Shrestha 2017 Review q2 wk
First Author
Table 40.2 (continued)
Khan 2017 Review at 1 mo 184 0.2% GTN: 92 62% 63% NR NR NR DTZ has better
62 5% Minoxidil: 30 76.5%
for 1 mo, then
q2 wk for
another mo
Emile 2020 Review q1 wk
160 100% Tocopherol
and 24 wk
Ruiz-Tovar 2022 Review at 2, 8
40 Chronic andRefractory Anal Fissure: What Are theTreatment Options?
https://t.me/medicina_free
No signicant
differences in
healing rates. BT
alone was better
Conclusions
tolerated.
Medical treatment
should be the rst
line treatment.
With the high
success rate, few
side-effects and
easy application,
isosorbide
dinitrate may be
the rst choice
for medical
treatment. LIS
remains the gold
standard.
455
(continued)
Incontinence
rate A/E
rate
pain
healing
NR 14.3% 1 pt with
Recurrence
Resolution of
Rate of
severe HA
(reported to
have these at
baseline)
in pain scores
after
treatment.
(58%
Moderate-
severe)
50% NR None 79% HA
20U BT + 0.1%
GTN: 20
3.9%
Ecchymosis.
6.9%
(Moderate; all
improved by 6
Bleeding.
3.9% Urinary
retention. 1%
Perianal
mo)
wetness.
77.1% NR 4.8% 0% 6.7% HA
0.25-0.5%
Isosorbide
dintrate: 105
(Dose increased
from 0.25% to
0.5% if not
healed after 1
mo)
41 20U BT: 21 57% No difference
12 wk
Yr F/U Pt, n Intervention: n
Comparing BT alone to BT + Topical medications
Asim 2014 Review at 6 and
First Author
207 LIS: 102 97.1% NR 1% 5.9%
3, 6 and 12 mo
Comparing LIS to Topical medications
Arslan 2012 Review at 1, 2,
456
https://t.me/medicina_free
LIS is an
effective, less
Conclusions
Anal
Incontinence
rate A/E
NR 2.9% (Gas) No HA. 1.5%
Recurrence
rate
7d
Resolution of
pain
painful, fast
recovery
treatment with an
often-
irritation.
1.5% Anal
abscess.
overestimated
incontinence rate.
Topical nifedipine
non-
compliance
causing
NR None 1.4% HA
7d
is effective but
side-effects can
and
withdrawal.
sometimes
compromise
compliance.
2.7% Anal
irritation.
LIS is better than
GTN and is the
gold standard
treatment.
None (other
than
incontinence)
Incontinence
to atus)
(20%
discontinued
Tx due to
G.-r. Han and N. Mishra
severe HA)
Rate of
healing
Yr F/U Pt, n Intervention: n
First Author
Table 40.2 (continued)
142 LIS: 68 88.2% 86.8% after
and 8 wk
De Rosa 2013 Review at 2, 4
68.9% 52.7% after
Warm anal
dilator with 0.3%
Nifedipine +
1.5%
Lidocaine: 74
2% GTN: 30 73.3% NR NR None 100% HA
Butt 2017 Review at 8 wk 60 LIS: 30 100% NR NR 3.3% (n=1;
40 Chronic andRefractory Anal Fissure: What Are theTreatment Options?
https://t.me/medicina_free
Treatment should
be
individualized.
BT has a higher
recurrence rate.
LIS provides
rapid and
permanent
recovery with a
LIS is the gold
standard when
clinicians would
Conclusions
like to avoid
recurrence and
obtain the best
pain relief. pLIS
can be considered
as an effective
alternative with
a lower risk of
incontinence.
Medical
treatment may be
tried as the rst
step.
higher risk of
457
(continued)
incontinence.
1% Perianal
abscess. 1%
Gas–
Incontinence
rate A/E
Recurrence
rate
Resolution of
pain
Rate of
healing
None
Thrombosed
hemorrhoids.
(gas–
resolved in 4
mo; 1% uid)
pLIS: 50 86% 84% 12% 2%
resolved in 6
mo)
1.3%
Arrhythmia.
2% DTZ: 150 68.7% 68% NR None 2% Nausea.
0.2% GTN: 150 62.7% 74% NR None 14.7% HA
(4% severe
HA).
4%
Hematoma.
8% Bleeding.
Persistent
intermittent
NR
incontinence
to gas/uid at
12 mo)
50U BT: 25 80% NR 48% 12% (No
incontinence
at 3 mo)
550 LIS: 200 93% 91% 4% 2% (1%
4 and 8 wk.
Yr F/U Pt, n Intervention: n
Acar 2020 Review at 1, 2,
First Author
50 LIS: 25 92% NR 12% 48% (4%
2 wk, and at 2,
3, 6, and 12 mo.
Comparing LIS to BT
Valizadeh 2012 Review at 1 and
458
https://t.me/medicina_free
BT is safer but
with less efcacy
Conclusions
4.2%
Bleeding.
Persistent gas
Incontinence
rate A/E
13.5% 10.4% (4.2%
Recurrence
rate
higher pain
Resolution of
pain
and its dose
needs to be
adjusted. LIS is
more effective
2.1%
Ecchymosis.
incontinence)
(Transient)
scores after 1
wk in LIS
than BT
group
but anal
sphincter tone
needs to be
assessed
preoperatively.
BT + DTZ can
be as effective as
pLIS in pt with sx
12 mo. In CAF
of longer
44% Urinary
retention. 8%
Pruritis.
6.2% Urinary
retention.
(Resolved
Persistent)
None 16% (2%
10% 4.1%
50% pain
score:
- pLIS: 94%
- BT + DTZ:
duration, pLIS
has a signicantly
higher cure rate.
4.1%
Ecchymosis.
36.7%
Pruritis.
after a few
days)
67.3%
G.-r. Han and N. Mishra
LIS remains the
gold standard.
TENS is
non-invasive and
without
complications. It
may be reserved
for pt who deny
8.1%
Hematoma.
Persistent
intermittent
gas
incontinence)
2.7% 8.1% (2.7%
improved
40.7% None None
pain at 1 mo
and 97.3% at
1 yr.
improved
pain at 1 mo
surgical
intervention.
and 44.4% at
1 yr
Rate of
healing
Yr F/U Pt, n Intervention: n
First Author
Table 40.2 (continued)
80U BT: 48 77.1% 2.3% 16.6%
96 LIS: 48 91.7% Signicantly
and at 1, 2, 3, 6,
9 and 12 mo.
Nour 2020 Review at 1 wk,
65.3% (Sx
12 mo = no
150U BT +
DTZ: 49
99 pLIS: 50 94% Reduction of
and at 1, 2, 6
and 12 mo.
Comparing pLIS to BT + Topical medications
Gandomkar 2015 Review at 1 wk,
difference.
Sx >12 mo =
pLIS
signicantly
higher)
73 LIS: 37 89.1% 100% with
Comparing LIS to TENS
Youssef 2015 Review at 1
day, 1 wk, and
at 1 and 3 mo,
and then q3 mo
x 1 yr.
TENS: 36 72.2% 75% with
Review at 1 and
3 mo, and then
q3 mo x1 yr.
40 Chronic andRefractory Anal Fissure: What Are theTreatment Options?
https://t.me/medicina_free
greatest healing
rate, lowest
recurrence rate,
greatest patient
satisfaction and
highest
improvements in
quality of life
with few
complications.
LIS is a better
treatment option
than ssurectomy.
There are less
postoperative
complications
but higher
recurrence rate
Conclusions
Tailored LIS
Incontinence
rate A/E
Recurrence
rate
4% 14% 4%
Resolution of
pain
with V-Y
advancement
ap has the
ischemia. 4%
Partial ap
Ecchymosis.
higher rate of
pain relief
with
combined
breakdown.
2% Sepsis.
Tailored LIS
+ V-Y
advancement
ap group
ischemia. 2%
Partial ap
breakdown.
2% Sepsis.
2%
Ecchymosis.
10% Urinary
retention.
incontinence.
12.5% Liquid
incontinence.
2.5% Solid
with LIS.
30% Urinary
retention.
incontinence.
incontinence.
32.5% Liquid
incontinence.
17.5% Solid
incontinence.
459
Rate of
healing
Yr F/U Pt, n Intervention: n
First Author
150 LIS: 50 88% Signicantly
and then 3, 6,
Comparing surgical procedures
Magdy 2012 Review at 1 wk,
70% 22% None 6% Flap
V-Y advancement
ap: 50
and 12 mo.
Seen in clinic if
sx developed.
96% 2% 2% 4% Flap
Tailored LIS +
V-Y advancement
ap: 50
80 LIS: 40 NR NR 5% 17.5% Gas
and then 1 and
2 mo, and then
telephone
Bara 2021 Review at 2 wk,
NR NR None 40% Gas
Anal dilatation +
conversation for
the next 6 mo.
Fissurectomy: 40
Abbreviations: Yr Year, F/U Follow-up, A/E Adverse events, NR Not reported, GTN Glyceryl trinitrate, DTZ Diltiazem, HA Headache, ED Erectile dysfunc-
tion, Pt Patients, Wk Weeks, Mo Months, Yr Years, BT Botulinum toxin injection, U Units, Tx Treatment, LIS Lateral internal sphincterotomy, pLIS Partial
lateral internal sphincterotomy, Sx Symptoms, TENS Transcutaneous electrical posterior tibial nerve stimulation
460
https://t.me/medicina_free
Conclusions
DTZ and GTN are equally effective, but DTZ has fewer
overall side-effects, HA, and recurrences; Therefore,
DTZ is the preferred rst line.
LIS was superior to BT in terms of healing and
recurrence rates. There was no signicant difference
between total complications, but BT caused less
incontinence.
90% chance of permanent cure. The incontinence risk
with LIS is higher than with BT but lower than with
anal stretch. Open pLIS may be equivalent to closed
pLIS in healing rates. Longer sphincter division may
be more effective at ssure healing. GTN has a higher
risk of HA.More evidence is needed to compare AAF
G.-r. Han and N. Mishra
to LIS.LIS may be offered as a rst-line treatment for
CAF, or it may be offered as back-up for those who fail
other treatments.
There was no difference in rates of healing or
recurrence, but BT had improved incidences of both
and a better side effect prole. There was a higher
incidence of transient incontinence with BT.
GTN: 243
Studies, n &
Study Type Pt, n Intervention: n
7 RCTs 481 DTZ: 238
Databases used;
time period
Medline,
EMBASE;
Inception to
Yr
First Author
Table 40.3 Systematic reviews and meta-analyses studying the treatment of chronic and refractory anal ssures
Sajid 2012 CCCG, Cochrane,
LIS: 241
7 RCTs 489 BT: 248
4/2011
PubMed, Web of
Chen 2014 MEDLINE,
Science,
Cochrane;
1996– 8/31/13
9 RCTs NR NR LIS is more effective than medical therapy or BT with a
1966– 1/2014.
EMBASE;
1980– 1/2014.
Cochrane;
Nelson 2014 Medline;
1966– 1/2014.
DARE, HTA; NR.
BT: 194
6 RCTs 393 GTN: 199
EMBASE,
Cochrane;
Sahebally 2017 PubMed,
Inception to
3/2017